Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Summary

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen ([email protected]).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications